CureVac Logo mit Claim RGB.jpg
CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA
June 13, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that it received a...
CureVac Logo mit Claim RGB.jpg
CureVac werden drei Patente zur intratumoralen Applikation von RNA erteilt
June 13, 2019 07:00 ET | CureVac AG
TÜBINGEN, Deutschland und BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gab die...
TBIO.jpg
Translate Bio to Present at the Jefferies 2019 Healthcare Conference
May 28, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
CureVac Logo mit Claim RGB.jpg
CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary
May 20, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, May 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it has entered into a...
TBIO.jpg
Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 16:23 ET | Translate Bio, Inc.
-- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq:...
TBIO.jpg
Translate Bio Announces $47.5 Million Private Placement
May 01, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 29, 2019 08:45 ET | Translate Bio, Inc.
LEXINGTON, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
CureVac Logo mit Claim RGB.jpg
CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies
April 16, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has been...
TBIO.jpg
Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors
April 11, 2019 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
CureVac Logo mit Claim RGB.jpg
CureVac to Participate in Upcoming Investor Conferences
April 09, 2019 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced its...